Baker BROS. Advisors LP Reduces Stake in Stoke Therapeutics, Inc. $STOK

Baker BROS. Advisors LP reduced its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 28.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,336,697 shares of the company’s stock after selling 1,297,141 shares during the period. Stoke Therapeutics accounts for approximately 0.6% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 25th largest position. Baker BROS. Advisors LP owned about 0.06% of Stoke Therapeutics worth $105,907,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Morgan Stanley grew its holdings in Stoke Therapeutics by 0.3% in the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after buying an additional 9,108 shares in the last quarter. Vanguard Group Inc. grew its holdings in Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares in the last quarter. State Street Corp grew its holdings in Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after buying an additional 1,072,176 shares in the last quarter. BVF Inc. IL grew its holdings in Stoke Therapeutics by 36.7% in the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after buying an additional 608,578 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after buying an additional 293,072 shares in the last quarter.

Stoke Therapeutics Trading Up 3.8%

STOK opened at $30.26 on Thursday. The stock’s 50-day moving average price is $32.07 and its 200 day moving average price is $32.35. Stoke Therapeutics, Inc. has a 12-month low of $11.17 and a 12-month high of $40.22. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -10.77 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The company had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on STOK. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wedbush upped their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Needham & Company LLC upped their price target on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, Wall Street Zen lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the sale, the insider owned 34,826 shares of the company’s stock, valued at $1,064,979.08. This trade represents a 4.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.